check_circleStudy Completed
Neuropathic pain associated with diabetic peripheral neuropathy, Peripheral neuropathic pain, Diabetes mellitus
Bayer Identifier:
19636
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
A study to learn how safe BAY2395840 is and how well it works in participants who have diabetic nerve pain
Trial purpose
Researchers are looking for a better way to treat people who have diabetic neuropathic pain (DNP), a condition in which diabetes results in pain due to nerve damage.
People with diabetes have high blood sugar levels. Over the time, high blood sugar levels can cause damage to the nerves in the body, which results in DNP. The nerve damage in this condition is localized in a stocking and glove like pattern and starts in the feet and can move upwards on your legs. Some patients also progress having pain in their fingers/hands. People with DNP have pain in these areas as well as reduction/loss of feeling, and at times light touch can feel like pain.
In this study, the researchers want to learn more about a new study treatment called BAY 2395840. BAY 2395840 works by blocking a receptor called the bradykinin B1 receptor, or B1R. This receptor is has been shown to play a role in pain perception.
The researchers also want to learn how well BAY 2395840 helps to reduce pain in the study participants. To answer this question, the researchers will measure how the participants’ pain changes after taking BAY 2395840 compared to a placebo. A placebo looks like a treatment but does not have any medicine in it. The researchers also want to learn how safe BAY 2395840 is for the participants to take.
The study will include adults.
This will be a “crossover” study. In a crossover study, all the participants will receive both treatments (BAY 2395840 and placebo), but in a different order. All participants in this study will take BAY 2395840 and a placebo as tablets by mouth.
There will be 2 periods in the study. Participants taking BAY 2395840 during period 1 will switch to placebo during period 2 and vice versa. There will some time for the switch from one period to another to make sure that whatever tablet you received in period 1 is gone from your system before period 2 starts to allow for the best possible evaluation of each tablet without any confusing effects.
The study is double blinded meaning that neither you nor your doctor will know which drug you are on. The sequence of double-blind placebo and BAY treatment will be determined randomly by a computerized system.
During the study, the participants will visit their study site 13 times. Each participant will be in the study for about 16 weeks. The treatment duration will be about 11 weeks.
During the study, the study team will:
• take blood and urine samples
• do physical examinations
• check the participants’ overall health
• check the participants’ heart health using an electrocardiogram (ECG)
• ask the participants about any medications they have been taking, and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
People with diabetes have high blood sugar levels. Over the time, high blood sugar levels can cause damage to the nerves in the body, which results in DNP. The nerve damage in this condition is localized in a stocking and glove like pattern and starts in the feet and can move upwards on your legs. Some patients also progress having pain in their fingers/hands. People with DNP have pain in these areas as well as reduction/loss of feeling, and at times light touch can feel like pain.
In this study, the researchers want to learn more about a new study treatment called BAY 2395840. BAY 2395840 works by blocking a receptor called the bradykinin B1 receptor, or B1R. This receptor is has been shown to play a role in pain perception.
The researchers also want to learn how well BAY 2395840 helps to reduce pain in the study participants. To answer this question, the researchers will measure how the participants’ pain changes after taking BAY 2395840 compared to a placebo. A placebo looks like a treatment but does not have any medicine in it. The researchers also want to learn how safe BAY 2395840 is for the participants to take.
The study will include adults.
This will be a “crossover” study. In a crossover study, all the participants will receive both treatments (BAY 2395840 and placebo), but in a different order. All participants in this study will take BAY 2395840 and a placebo as tablets by mouth.
There will be 2 periods in the study. Participants taking BAY 2395840 during period 1 will switch to placebo during period 2 and vice versa. There will some time for the switch from one period to another to make sure that whatever tablet you received in period 1 is gone from your system before period 2 starts to allow for the best possible evaluation of each tablet without any confusing effects.
The study is double blinded meaning that neither you nor your doctor will know which drug you are on. The sequence of double-blind placebo and BAY treatment will be determined randomly by a computerized system.
During the study, the participants will visit their study site 13 times. Each participant will be in the study for about 16 weeks. The treatment duration will be about 11 weeks.
During the study, the study team will:
• take blood and urine samples
• do physical examinations
• check the participants’ overall health
• check the participants’ heart health using an electrocardiogram (ECG)
• ask the participants about any medications they have been taking, and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Key Participants Requirements
Sex
AllAge
18 - N/ATrial summary
Enrollment Goal
80Trial Dates
February 2022 - November 2022Phase
Phase 2Could I Receive a placebo
YesProducts
BAY2395840Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Klinische Forschung Berlin GbR | Berlin, 10787, Germany |
Completed | Klinische Forschung Karlsruhe GmbH | Karlsruhe, 76137, Germany |
Completed | Klinische Forschung Schwerin GmbH | Schwerin, 19055, Germany |
Withdrawn | Siteworks GmbH Fulda | Fulda, 36037, Germany |
Completed | Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW) | Bad Oeynhausen, 32545, Germany |
Completed | Klinische Forschung Hannover-Mitte GmbH | Hannover, 30159, Germany |
Completed | Complexo HU Ferrol | Endocrinología y Nutrición | Ferrol, 15405, Spain |
Completed | Hospital Univ. Bellvitge | Anestesiología y Unidad del Dolor | L'Hospitalet de Llobregat, 08907, Spain |
Completed | Hospital Gregorio Maranon | Endocrinology Department | Madrid, 28007, Spain |
Completed | Hospital General Universitario de Alicante | Alicante, 03010, Spain |
Withdrawn | Hospital Universitario Virgen de las Nieves | Granada, 18014, Spain |
Completed | Gerencia de Gestion Integrada A Coruna | Department of Endocrinology and Nutrition | A Coruna, 15006, Spain |
Completed | DRC Gyogyszervizsgalo Kozpont Kft. | Balatonfured, 8230, Hungary |
Completed | Clinexpert Kft. | Budapest, 1033, Hungary |
Withdrawn | Semmelweis University | Budapest, 1083, Hungary |
Completed | ALIAN s.r.o. | Bardejov, 085 01, Slovakia |
Completed | Vseobecna nemocnica v Ziari nad Hronom | Ziar nad Hronom, 965 37, Slovakia |
Completed | Neuron - D.T. sro, Neurologicka ambulancia | Zilina, 010 01, Slovakia |
Completed | NEUROPOINT sro, Neurologicka ambulancia | Bratislava, 851 01, Slovakia |
Completed | Internal and Diabetes Clinic - IN-DIA s.r.o. | Lucenec, Slovakia | Lucenec, 984 01, Slovakia |
Completed | Diabetologicka ambulance Vlasim | Vlasim, 258 01, Czechia |
Completed | Interni a diabetologicka ambulance - Krnov | Krnov, 794 01, Czechia |
Completed | Fakultni nemocnice Ostrava | Ostrava, 708 52, Czechia |
Completed | King's College Hospital - NHS Foundation Trust | London, SE5 9RS, United Kingdom |
Withdrawn | Royal Hallamshire Hospital | Sheffield, S10 2JF, United Kingdom |
Completed | MAC Research Centre - Manchester | Manchester, United Kingdom |
Completed | MAC Clinical Research - Teesside | Teesside, TS17 6EW, United Kingdom |
Completed | Vseobecna fakultni nemocnice v Praze | Praha 2, 12808, Czechia |
Completed | NEUROHK s.r.o | Chocen, 565 01, Czechia |
Completed | PRAGLANDIA | Praha 5, 150 00, Czechia |
Completed | Medivasa s.r.o. | Zilina, 01001, Slovakia |
Completed | InnoDiab Forschung GmbH | Essen, 45136, Germany |
Completed | Vestra Clinics s.r.o. | Rychnov nad Kneznou, 516 01, Czechia |
Completed | COROMED SMO KFT | Pecs, 7623, Hungary |
Primary Outcome
- Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of interventionNRS is an one-item assessment of average neuropathic pain intensity which is presented as an 11-point Likert scale with 0 as “no pain” and 10 as “worst imaginable pain”.date_rangeTime Frame:Baseline to end of intervention (in total up to 16 weeks)
Secondary Outcome
- Change in Neuropathic Pain Symptom Inventory (NPSI) score from baseline to the end of intervention.The Neuropathic Pain Symptom Inventory (NPSI) is a PRO developed to evaluate different symptoms of neuropathic pain.date_rangeTime Frame:At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).
- Change in Patient Global Impression of Severity (PGI-S) score from baseline to the end of intervention.The PGI-S is a one-item self-reported instrument used to assess to assess patients’ impression of disease severity with a 6-point scale response options, scores ranging from 1 ("none") to 6 ("very severe).date_rangeTime Frame:At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).
- The proportion of participants achieving a ≥30% and a ≥50% reduction in weekly mean 24-hour average pain intensity score (i.e. responder rates using NRS)date_rangeTime Frame:From baseline to end of intervention (in total up to 12 weeks)
- Number of participants with treatment emergent adverse events (TEAE)date_rangeTime Frame:From start of study intervention to 14 days after last dose.
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
RandomizedBlinding
N/AAssignment
Crossover AssignmentTrial Arms
2